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Dabigatran etexilate (DE), rivaroxaban, and apixaban are nonvitamin K antagonist oral anticoagulants (NOACs) that have been
compared in clinical trials with existing anticoagulants (warfarin and enoxaparin) in several indications for the prevention and
treatment of thrombotic events. All NOACs presented bleeding events despite a careful selection and control of patients. Compared
with warfarin, NOACs had a decreased risk of intracranial hemorrhage, and apixaban and DE (110mg BID) had a decreased risk
of major bleeding from any site. Rivaroxaban and DE showed an increased risk of major gastrointestinal bleeding compared with
warfarin. Developing strategies to minimize the risk of bleeding is essential, as major bleedings are reported in clinical practice
and specific antidotes are currently not available. In this paper, the following preventive approaches are reviewed: improvement of
appropriate prescription, identification of modifiable bleeding risk factors, tailoring NOAC’s dose, dealing with a missed dose as
well as adhesion to switching, bridging and anesthetic procedures.
1. Introduction
Nonvitamin K antagonist oral anticoagulants (NOACs) [1]
have been approved by the European Commission, as an
alternative to vitamin K antagonists (VKAs) and parenteral
anticoagulants, for the following indications: prevention of
venous thromboembolism (VTE) in adult patients undergo-
ing elective hip or knee surgery (apixaban [2–4], dabigatran
etexilate (DE) [5–7], and rivaroxaban [8–11]), prevention
of stroke and systemic embolism in adult patients with
nonvalvular atrial fibrillation (NVAF) (apixaban [12], DE [13],
and rivaroxaban [14]), treatment and secondary prevention of
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deep vein thrombosis (DVT) and pulmonary embolism (PE)
in adults (rivaroxaban and DE [15, 16]), and prevention of
atherothrombotic events after an acute coronary syndrome
with elevated cardiac biomarkers, combined with a single
or dual antiplatelet therapy (acetylsalicylic acid alone or
associated with clopidogrel or ticlopidine) (rivaroxaban [17,
18]). In NVAF trials, NOACs proved to be either superior
or noninferior to warfarin for the prevention of stroke
and systemic embolus [12–14]. Several guidelines (European
Society of Cardiology, American College of Chest Physicians,
and Canadian Cardiovascular Society) recommend NOACs
as broadly preferable to VKAs in most patients with NVAF.
This will lead to a wider use of NOACs in the future.
Compared with warfarin, the NOACs showed less risk
of intracranial hemorrhage, and apixaban and DE (110mg
bid) showed less risk of major bleeding from any site [12–
14]. Unfortunately, rivaroxaban and DE had an increased risk
of gastrointestinal (GI) bleeding compared with warfarin.
Apixaban was associated with fewer GI bleeding compared
with warfarin, but it was not statistically significant [19].
Bleeding events were reported despite a regular moni-
toring of adverse events, a strong medication adherence and
a careful selection of patients in the pivotal clinical trials
(exclusion of patients with assumed poor compliance, bleed-
ing risks, renal insufficiency, etc.). Extension of adverse events
into clinical practice is currently under research and postmar-
keting registers, like the GLORIA-AF registry, are recruiting
[20, 21].
The aim of this review is to highlight the bleeding risks
with NOACs in the clinical practice and to broach different
prevention strategies to minimize these adverse events.
2. NOACs and Major Bleeding
Large randomized controlled trials (RCT) allowing head-to-
head comparison between NOACs are not available. Only
indirect comparison on bleeding can be proposed since the
three pivotal NOAC trials contain a common comparator
(i.e., adjusted-dose warfarin). Even so there are limits in
the conclusiveness of such comparisons, like differences in
the study populations (differences in reporting age, renal
function, exclusion criteria, and additional risk factors), in
the definition of adverse events, in study protocols (open or
double-blind design) and in time in therapeutic range (TTR)
of the international normalized ratio (INR) values among
these RCTs. In the three pivotal trials comparingNOACswith
warfarin, evidence of the validation of the stated INR was not
provided. This makes cross-trial comparisons difficult [30–
32].
Few data exist regarding the safety of NOACs in clinical
practice, and the available information reflects the limitations
of post-authorization studies, such as reporting bias. Recent
evidence provides contradiction to earlier safety reports that
suggested that the major bleeding rates in patients receiving
NOACs in clinical practice did not exceed the rates reported
in the pivotal trials [21, 33].
McConeghy et al. evaluated DE adverse event reports
with a reported bleeding event and/or reported fataloutcome
compared with warfarin [34]. This retrospective analysis of
the FDA Adverse Event Reporting System (FAERS) database
suggested increased odds of bleed-relatedmortality in clinical
practice with dabigatran compared with the clinical trials
[34].
The bleeding reports were driven by patients who were
older, renally impaired, acutely injured, and had low body
weight. These patients were underrepresented in the RELY
trial and may have higher risks of dabigatran-induced bleed-
ing. Furthermore, reports from FAERS showed underreport-
ing bias [34].
For rivaroxaban, the following clinical characteristics
were associated with an increased risk for major GI
bleeding [32]: concurrent aspirin or nonsteroidal anti-
inflammatory drugs (NSAID) use, prior vitamin K antag-
onist use, decreased creatinine clearance, prior stroke,
transient ischemic attack or systemic embolization, sleep
apnea, cigarette smoking, chronic obstructive pulmonary
disease, male gender, patient treated with histamine-2
receptor antagonist or proton pump inhibitor (PPI), and
prior upper and lower GI bleeding. Most of these char-
acteristics were also associated with an increased risk
of major GI bleeding in patients treated with warfarin
[32].
Concerning apixaban, Hylek et al. recently analyzed the
bleeding events of all patients who received at least one
dose of a study drug in the ARISTOTLE trial. All major
bleedings (defined by the criteria of the International Society
on Thrombosis and Haemostasis (ISTH)) that appear from
the time of the first dose until 2 days after the last dose was
received were included [19]. Apixaban, compared with war-
farin,was associatedwith a 31% reduction of firstmajor bleed-
ing andwith half of the deathwithin 30 days following amajor
hemorrhage. Independent factors associated with first major
hemorrhage were: older age, prior hemorrhage, prior stroke
or transient ischemic attack (TIA), diabetes, lower creatinine
clearance, and decreased hematocrit. Female gender and liver
disease were more associated with apixaban randomization,
compared with warfarin. A subgroup analysis showed that
patients with renal dysfunction and low body weight had a
greater reduction in bleeding with apixaban versus warfarin
than in patients with normal renal function and higher body
weight.
The use of aspirin and nonsteroidal anti-inflammatory
drugs (NSAID) with apixaban increased independently the
risk of major bleeding by around 30% [19].
Based on the RE-LY trial, DE 150mg BID, combined with
a single or dual antiplatelet therapy, increased the rate of
extracranial bleeding [35].
A brief summary of NOAC’s pharmacology is available in
Table 1 [22–25].
3. Prevention of Major Bleeding in Patients
Receiving NOACs
The following preventive strategies are achievable to reduce
the incidence rate of NOAC-related major bleeding:
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Table 1: Summary of pharmacokinetic properties of nonvitamin K antagonist oral anticoagulants (NOACs) [22–25].
Dabigatran Rivaroxaban Apixaban
Target Factor lla Factor Xa Factor Xa
Prodrug Yes No No
Tmax (h) 1.5–3.0 2.0–4.0 3.0–4.0
Distribution volume
(L) 60–70 ±50 23
Half-life (h) 11: healthy individuals12-13: elderly
5–9: healthy individuals
11–13: elderly 8–15: healthy individuals
Bioavailability 3–7%pH sensitive
80–100%: 10mg
66%: 15–20mg under fasting
conditions
±50%
Protein binding 35% >90% 87%
Metabolism Conjugation CYP-dependent andindependent mechanism
CYP-dependent
mechanism
Active metabolites Yes glucuronide conjugates No No
Elimination
80% renal 33% unchanged via the kidney 25% renal
20% bile (glucuronide
conjugation)
66% metabolized in the liver into
inactive metabolites then
eliminated via the kidney or the
colon in an approximate 50%
ratio
75% through the liver while
the residue is excreted by
the hepatobiliary route in
the feces
Effects of food Tmax delayed;Cmax and AUC unchanged
Tmax delayed;
Cmax and AUC increased (76%
and 30–40%, respectively)
Tmax delayed;
Cmax and AUC unchanged
CYP substrate No CYP3A4, CYP2J2 CYP3A4
P-gp substrate DE: yes Yes Yes
(1) improving appropriate prescription,
(2) identifying modifiable bleeding risk factors,
(3) improving individual benefit-risk by tailoring
NOACs dose,
(4) dealing with a missed dose,
(5) adhering to switching procedures,
(6) adhering to bridging procedures,
(7) adhering to anesthetic recommendations.
3.1. Improving Appropriate Prescription
3.1.1. Off-Label Use or Misuse. The off-label use or misuse
of NOACs means a use outside an appropriate indication or
at inappropriate doses. For example the off label uses of DE
are: age >80 years, patients with liver or kidney disease, with
previous bleeding, with previous ischemic heart disease or
severe renal impairment, patients with a CHADS
2
score of
0 and patients with coadministration of systemic ketocona-
zole, cyclosporine, itraconazole, tacrolimus, dronedarone
and aspirin [36–41].
Misuse is frequent (between 8.0 and 43.5%) and can
induce supratherapeutic anticoagulation with a potential risk
of severe or even fatal bleeding [36–38]. A lack of consensus
in NVAF’s definition and the complexity of dose regimens
for different indications and populations (as illustrated in
Table 2) can lead to inadequate prescriptions.
Because of an increased risk of bleeding, NOACs should
be used with caution if a concomitant use of antiplatelet
agents is indicated [42–44], and NSAIDs should be avoided
if possible.
3.1.2. Renal Function. Several cases of severe bleedings (often
leading to death) have been reported in older patients
under DE [45]. Renal failure was the most recurrent risk
factor associated with bleedings in these elderly patients
and should therefore be reassessed during the treatment if
clinically indicated (fluctuating renal function, diuretic use,
and hypovolemia).
In clinical trials of DE and rivaroxaban for NVAF,
drug eligibility and dosing were determined by using the
Cockcroft-Gault equation to estimate creatinine clearance
(CrCl), a measure of renal function. The modification of
diet in renal disease (MDRD) equation (used to estimate
glomerular filtration rate (eGFR)) leads, in low GFR values,
to a surestimated renal function in comparison with the
Cockcroft-Gault equation [46, 47].Thus, by using theMDRD
equation,many elderly patients withAFwould either become
incorrectly eligible for these drugs or would receive higher
doses than required. Regulatory authorities and drug com-
panies recommend therefore the use of the Cockcroft-Gault
equation instead of the MDRD-derived eGFR to calculate
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Table 2: Indication and dose regimens of Dabigatran etexilate, Rivaroxaban, and Apixaban [2–18].
Dabigatran etexilate Rivaroxaban Apixaban
VTE
Prophylaxis
220mg/day
(2 capsules of 110mg OD)
or
150mg/day
(2 capsules of 75mg OD)
→ if CrCl 30–50mL/min, if
>75 ys, if verapamil, amiodarone
and quinidine
THR: 28–35 days
TKR: 10 days
10mg/day
(1 tablet of 10 mg OD)
THR: 5 weeks
TKR: 2 weeks
5mg/day
(1 tablet of 2.5mg BID)
THR: 32–38 days
TKR: 10 days
Nonvalvular
atrial fibrillation
300mg/day
(1 capsule of 150mg BID)
220mg/day (EU)
(1 capsule of 110mg BID)
→ if >80 ys or verapamil
150mg/day (US)
(1 capsule of 75 mg BID)
→ if CrCl between 15–30mL/min
20mg/day
(1 tablet of 20mg OD)
15mg/day
(1 tablet of 15mg OD)
→ if CrCl between 15–49mL/min
10mg/day
(1 tablet of 5mg BID)
5mg/day
(1 tablet of 2.5mg BID)
→ if at least 2 of the
following conditions:
≥80 ys, ≤60 kg or serum
creatinine ≥1.5mg/dL;
or if CrCl 15–29mL/min
VTE treatment
Adopted indication by the
CHMP on 25th April 2014 (EU)
300mg/day (US)
(1 capsule of 150mg BID) after
5–10 days of parenteral
anticoagulation
Treatment phase: 30mg/day
(1 tablet of 15mg BID) for 21 days
Secondary prevention:
20mg/day
(1 tablet of 20mg OD)
15mg/day
(1 tablet of 15mg OD)
→ if CrCl between 15-49mL/min
and the risk of bleeding
outweighs the risk of recurrent
DVT or PE
×
Prevention of
atherothrom-
botic events
after ACS with
elevated cardiac
biomarkers
×
5mg/day
(1 tablet of 2.5mg BID)
in association with ASA
(75–100mg) alone or ASA +
clopidogrel (75mg)
×
×Off-label; BID: twice daily; CrCl: creatinine clearance; DVT: Deep-vein thrombosis; OD: once daily; PE: pulmonary embolism; THR: total hip replacement;
and TKR: total knee replacement; vte: venous thromboembolism; CHMP: committee for medecinal products for human use.
eligibility for NOACs and adapted dose for elderly patients
with AF.
3.1.3. Bioavailability. By opening DE capsules, the bioavail-
ability reaches 75% and increases highly the bleeding risk
[43]. Therefore, gastrostomies and jejunostomies are not
advised with DE.
For rivaroxaban, Moore et al. studied its relative bioavail-
ability when administered as a whole tablet orally or as a
crushed tablet mixed with applesauce or water suspension
through a nasogastric tube (NGT) or a gastrostomy. There
was no difference in both pharmacokinetics, so that they
concluded to a safe administration for rivaroxaban through
a NGT or gastrostomy [48].
To the best of our knowledge, there is currently no data
available for apixaban.
3.1.4. Patient with Low Body Weight. Despite recent data
suggesting that the clearance of anticoagulants increases with
weight, the optimal dosing strategies for most anticoagulants
remain unknown [49].This uncertainty is mainly relevant for
anticoagulants with fixed-dosing regimen such as NOACs, in
contrast to anticoagulants for which efficacy monitoring is
routinely required (i.e., VKAs).
In the RE-LY study, the overall mean weight of patient
was 82.6 kg (ranging from 32 to 222 kg) with 17.1% of patients
weighing above 100 kg. A tendency of increasing dabigatran
concentrations with decreasing body weight was found [49].
There is very limited clinical experience in patients with a
body weight <50 kg. In this population, no dose adjustment
is advised but a close clinical surveillance is recommended by
the different authorities [43, 50].
A study with 48 healthy participants assessed the influ-
ence of extremes of body weight (≤50 kg and >120 kg) on
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the pharmacokinetics (PK) of rivaroxaban 10mgOD as com-
pared with normally weighted patients (80 kg). The results
show that the 𝐶max of rivaroxaban was increased by 24%
in subjects weighing ≤50 kg while the area under the curve
(AUC) was unaffected (difference is <25%) by body weight.
The 24% increase in 𝐶max in patients with low body weight
resulted in a small (15%) increase in prolongation of pro-
thrombin time (PT), which was not considered as clinically
relevant [51]. However, this was performed with STA Neo-
plastin CI+, a reagent with a moderate sensitivity to rivarox-
aban. In a population pharmacokinetic/pharmacodynamics
(PK-PD) modeling study, there was a clear increase in the
volume of distribution interrelated with weight and probably
due to secondary increase of body volume [52]. Based on
these findings, a higher exposure to rivaroxaban could be
expected in patients with low body weight and, consequently,
a higher risk of bleeding with a standard dose. However,
these preliminary data need confirmations in larger studies.
Similarly to dabigatran, no dose adjustment is currently
proposed by the European and American agencies in patients
with extreme body weight (<50 kg or >120 kg) [42].
Apixaban has also been evaluated in patients with
extreme body weight. A 30% and 20% increase in 𝐶max
and AUC, respectively, has been seen in patients weighing
<50 kg [53]. These modifications were considered as modest
and unlikely to be clinically meaningful. However, further
evaluation of clinical data is warranted. Since the bodyweight
seems to have a modest effect on apixaban exposure, the
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) recommend dose adjustment in
patients weighing <60 kg (2.5mg BID instead of 5mg BID) in
the presence of additional risk factors, namely, age ≥80 years
or serum creatinine >1.5mg/dL [54, 55].
3.1.5. Patients with Impaired Hepatic Function. Hepatic
impairment may alter the pharmacokinetics of drugs that are
metabolized by the liver, such as rivaroxaban and apixaban
[56]. Data on the use of NOACs in hepatic impairment
are scarce and mainly restricted to single-dose studies in a
limited number of subjects with mild or moderate hepatic
impairment. In addition, patients with elevated liver enzymes
and/or bilirubin levels were excluded from clinical trials. The
manufacturer’s recommendations for rivaroxaban, apixaban,
and DE regarding impaired hepatic function are based on
both Child-Pugh classification and liver-related exclusion
criteria applied in clinical trials [57].
Stangier et al. found no influence of moderate hepatic
impairment on pharmacokinetic, pharmacodynamics and
safety profile of DE following administration of a single
150mg dose in 24 subjects [56]. However, patients with ele-
vated liver enzymes above 2 times the upper limit of normal
(ULN) were excluded from clinical trials [43]. The Summary
of ProductCharacteristics of the EuropeanCommission (EU-
SmPC) contraindicates the use of DE in patients with hepatic
impairment or liver disease expected to have any impact on
survival [43].
In contrast to dabigatran, liver metabolism is an impor-
tant route of elimination for FXa inhibitors. Approximately
two-thirds of the administered rivaroxaban dose is metab-
olized by the liver via CYP3A4, 2J2, and CYP-independent
mechanisms to inactive metabolites [42].The AUC following
administration of a single dose of rivaroxaban 10mg was
increased by 2.27-fold in patients with moderately impaired
liver function (Child-Pugh B).Moderate but notmild hepatic
impairment reduced total body clearance of rivaroxaban and
led to pharmacodynamics effects [58]. Therefore, EMA con-
traindicates its use in case of hepatic disease associated with
coagulopathy and clinically relevant bleeding risk including
cirrhotic patients with Child Pugh B and C.
Apixaban undergoes liver metabolism mainly via
CYP3A4/5, but other isoenzymes are also involved [44].
Data on the use of apixaban in patients with moderate
hepatic impairment (Child Pugh B) show that AUC
increased slightly by 1.09-fold when a 5mg single dose was
administered [59]. Apixaban should be used with caution in
patients with elevated liver enzymes (ALT/AST > 2 × ULN)
or total bilirubin ≥ 1.5 × ULN because those were excluded
from clinical trials. The EMA recommends to perform
liver function test prior to initiating apixaban and to use it
with caution in patients with moderate and severe hepatic
impairment. Apixaban is contraindicated in patients with
hepatic disease associated with coagulopathy and clinically
relevant bleeding risk [44].
In conclusion, limited data indicate that the PK and PD
of NOACs such as rivaroxaban or apixaban can be modified
in moderate hepatic impairment, in contrast to dabigatran.
Further evaluations are needed to better support clinicians in
their decision process. Evaluations of liver function are rec-
ommended before prescribing NOACs and regularly during
treatment in patients with possible liver impairment.
3.1.6. Drug Interactions. In addition to these specific pop-
ulations, NOACs have also drug interactions with P-
glycoprotein substrates orCYP3A4 inhibitors thatmay highly
increase their plasma concentrations and hence bleeding
risks. Table 3 summarizes drug-drug interactions reported in
the literature as well as recommendations for dose adaptation
and contraindications for the EU-SmPCandFDAprescribing
guidelines [26–28].
3.2. Identifying Modifiable Bleeding Risk Factors. Identifica-
tion of modifiable and nonmodifiable bleeding risk factors
will help to ascertain and manage the risk of major bleed-
ing. This can be performed before NOAC’s initiation using
validated bleeding scores like the International Society of
Thrombosis and Hemostasis bleeding assessment tool [60].
TheHAS-BLED score is a tool designed for assessing bleeding
risks during anticoagulation. Despite debate in the literature
on its ability to predict any clinically relevant bleeding, it
may be useful for this purpose [61, 62]. For example, a
HAS-BLED score ≥3 indicates high risk for hemorrhage and
suggests thatmodifiable risk factors affecting bleeding should
be reviewed and corrected (e.g., blood pressure, hepatic/renal
function, INR, antiplatelet agents,NSAIDs, alcohol ingestion,
and selective serotonin reuptake inhibitors (SSRI)).
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Table 3: Summary of drug-drug interactions provided in the literature. When available, recommendations for dose adaptation or
contraindications by the competent authorities are provided [26–28].
Molecule Mechanism Dabigatran Rivaroxaban Apixaban
Antiarrhythmics
Dronedarone P-gp and CYP 3A4
inhibitor
AUC: +114% (400mg:
single dose)∗
Minor effect (use with
caution if CrCl
15–50mL/min)∗∗∗
No data yet
AUC: +136% (400mg:
multiple doses)
Quinidine P-gp competition
AUC: +53%
(1,000mg: single
dose)∗∗
Minor effect (use with
caution if CrCl 15–50
mL/min)
No data yet
Verapamil P-gp competition and
weak CYP 3A4
inhibitor
AUC: +18% (120mg
IR: single dose taken
2 h after DE intake)∗∗
Minor effect (use with
caution if CrCl
15–50mL/min)
No data yet
AUC: +143% (120mg
IR: single dose, 1 h
before DE intake)∗∗
Cmax: +12% (120mg
IR: single dose taken
2 h after DE intake)∗∗
Cmax: +179% (120mg
IR: single dose, 1 h
before DE intake)∗∗
Amiodarone P-gp competition AUC: +58% (600mg:single dose)∗∗
Minor effect (use with
caution if CrCl 15–50
mL/min)
No clinically
relevant effect
Diltiazem P-gp and CYP 3A4inhibitor No effect
Minor effect (use with
caution if CrCl 15–50
mL/min)
AUC: +40%
Antianginal/antihypertensive drugs
Ranolazine P-gp and CYP 3A4inhibitor No data yet
Minor effect (use with
caution if CrCl
15–50mL/min)
No data yet
Felodipine P-gp and CYP 3A4inhibitor No data yet
Minor effect (use with
caution if CrCl
15–50mL/min)
No data yet
Anti-inflammatory
Naproxen P-gp competition No data yet AUC: +10% (500mg) AUC: +50%
Antihypercholesterolemiant
Atorvastatin P-gp and CYP 3A4substrate AUC: +18% No effect
No PK data
yet
Antimycotic
Ketoconazole P-gp and CYP 3A4inhibitor
AUC: +138% (400mg:
single dose)∗
Cmax: +72% (400mg:
single dose)
Cmax: +62%
(400mg od)
AUC: +153% (400mg:
multiple doses)
AUC: +158% (400mg:
single dose)
AUC: +100%
(400mg od)
Itraconazole P-gp and CYP 3A4inhibitor No data yet
∗ No data yet, but similar
results than ketoconazole
are expected
No data yet,
but similar
results than
ketoconazole
are expected
Voriconazole P-gp and CYP 3A4inhibitor No data yet
Posaconazole P-gp and CYP 3A4inhibitor No data yet
∗∗∗ No data yet
Fluconazole CYP 3A4 inhibitor No data yetSupposed no effect Cmax: +28% No data yet
AUC: +42%
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Table 3: Continued.
Molecule Mechanism Dabigatran Rivaroxaban Apixaban
Antibacterial
Clarithromycin
P-gp and CYP 3A4
inhibitor Cmax: +49% No data yet
AUC: +60% AUC: +54% (500mg bid)
Azithromycin P-gp and CYP 3A4inhibitor No data yet
Minor effect (use with
caution if CrCl
15–50mL/min)
No data yet
Erythromycin P-gp and CYP 3A4inhibitor No data yet AUC: +34% (500mg tid) No data yet
Protease inhibitors
Ritonavir P-gp and CYP 3A4inhibitor No data yet
∗∗∗ Cmax: +55% (600mg bid)
No PK data
but strong
increase
AUC: +153% (600mg bid)
Immunosuppressor
Cyclosporine P-gp competition No data yet∗ AUC: +50% No data yet
Tacrolimus P-gp competition No data yet∗ AUC: +50% No data yet
∗The FDA recommends reducing the dabigatran etexilate at 75mg bid for stroke prevention in NVAF. No recommendations are given by the FDA for
cyclosporine, tacrolimus, and itraconazole.
∗∗The EMA contraindicates concomitant treatment with these drugs. EMA recommends dose reduction from 220mg od to 150mg od in major orthopedic
surgery and from 150mg bid to 110mg bid in stroke prevention in patients with NVAF. No dose recommendation is provided by the FDA.
∗∗∗Not recommended by the EMA.
The EMA has introduced new contraindications for all
NOACs since September 2013. This statement mentions that
a screening of injuries and sicknesses that may lead to major
bleeding is required before startingNOAC therapies.This can
be a current or recent gastrointestinal bleeding, suspected
or known esophageal varicose veins, any malignancy with
high bleeding risks (e.g., colon cancer), recent cerebral,
spine or ophthalmic injuries, recent intracranial hemorrhage,
arteriovenous malformations, vascular aneurysm, or major
intraspinal and intracranial vascular anomalies [32].
Careful attention must be directed to renal protective
strategies for patients under DE. These patients should
know that concurrent medications (e.g., NSAIDs) or clinical
comorbidities (e.g., dehydration) can deteriorate their renal
function, and, as consequence, increase and prolong dabiga-
tran anticoagulant effect [32].
3.3. Improving Individual Benefit-Risk by
Tailoring NOAC’s Dose
3.3.1. Why? A reanalysis of the RE-LY study has shown
that bleeding outcomes were correlated with dabigatran
plasma concentrations [63]. Demographic characteristics
(mainly age and previous stroke) played the strongest role in
determining risk of clinical events. In addition, the authors
concluded that for patients at highest risk for events, such as
the very elderly and/or those with poor renal function, an
adjustment of dabigatran dose to optimize exposure might
improve benefit-risk ratio if they are at either extreme of the
concentration range.
The EU-SmPC mentions that exceeding the 90th per-
centile of NOAC’s trough level is considered to be associated
with an increased risk of bleeding. For example, patients
treated with 150mg dabigatran BID for stroke prevention in
NVAFhave a 90th percentile of dabigatran plasma concentra-
tions measured at trough (10–16 hours (h) after the previous
dose) about 200 ng/mL [43].
Moreover, estimation of plasma drug concentrations can
also be interesting to identify high responders which are at
risk of bleeding [64]. Pharmacokinetic studies showed that
dabigatran has considerable variation in plasma drug concen-
trations [65]. Most patients will obtain an adequate plasma
level when given a fixed dose. But a measurable proportion
will either achieve an insufficient or a supratherapeutic drug
level [66–68]. Furthermore, medication adherence is not
better than 50% in unmonitored conditions [64, 69],meaning
that losing track of the patients during long-term (often
life-long) treatment can be worrying. For these reasons,
searching for the optimal dose in patients at risk of supra-
or infratherapeutic plasma level can improve the efficacy
and safety of NOACs. In addition, without a structured
organization, there will be no routine check on side effects,
tolerance, and adherence [64, 69].
3.3.2. When? To prevent massive bleeding, biological moni-
toring would be valuable in the following situations [64, 68,
70, 71]:
(i) before urgent surgery or procedure (with the last
administration in the last 24 h, or more, if CrCl <
50mL/min),
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(ii) before fibrinolytic therapy of acute ischemic stroke,
(iii) for bridging therapy,
(iv) for patients with multiple risk factors for NOAC’s
accumulation (i.e., patients older than 75 years, drug-
drug interactions as with frequently used medication
like amiodarone and verapamil, extreme body weight
(<50–60 kg and >110–120 kg), hepatic impairment,
and renal impairment),
(v) for patients with renal impairment (progressive
decrease of renal function, acute decrease due to
dehydration, antibiotics administration, etc.),
(vi) in complex management of dual or triple antithrom-
botic therapies (e.g., patients with AF undergoing
percutaneous coronary intervention or dual platelet
inhibitors added to NOACs).
3.3.3.How? NOACs affect all routine coagulation assays [72].
The maximum effect of NOAC on clotting tests occurs at the
same time as their maximal plasma concentrations (Table 1).
Therefore, it is essential to know the timing of NOAC’s
administration and the timing of blood sampling when
interpreting results of a coagulation assay in a NOAC treated
patient.
For example, coagulation assay results will differ if blood
samples are taken 2 hours after DE intake (peak level)
compared with blood sampling 12 hours after ingestion of
the same dose. A French group (GIHP: Groupe d’Inte´reˆt
en He´mostase Pe´riope´ratoire) proposed the following cut-
off for the perioperative management of DE and rivarox-
aban (Table 4): <30 ng/mL: the operation may take place;
between 30 and 200 ng/mL: therapeutic zone; between 200
and 400 ng/mL:minor hemorrhagic risk; >400 ng/mL:major
hemorrhagic risk [29].
For apixaban, there is no data regarding the plasma
trough or max level versus bleeding or recurrence of throm-
bosis. Pharmacokinetic studies revealed that apixaban plasma
concentrations variedmodestly between peak and trough and
were mainly comprised within the range of 100–300 ng/mL
[73].
The recent recommendation of the International Soci-
ety of Thrombosis and Hemostasis (ISTH) mentions that
the activated partial thromboplastin time (aPTT) and pro-
thrombin time (PT) can be used in emergency situations
to determine the relative intensity of anticoagulation due
to DE and rivaroxaban, respectively [72]. However, aPTT
and PT should not be used to quantify the drug plasma
concentration. Further studies are required to determine the
relative sensitivity of aPTT and PT reagents in order to give
more specific recommendations. In addition, aPTT and PT
are global assays which are not reflecting peripheral concen-
trations of NOACs, especially at high plasma concentrations
[72].
PT is not sensitive enough to estimate apixaban plasma
concentrations. Furthermore, depending on the reagent, it
may be normal with apixaban therapeutic concentration.
Even for the most sensitive reagents, it may only inform the
clinician if the patient is taking the drug.
Table 4: Perioperative management of NOACs (dabigatran and
rivaroxaban)—proposal for recommendations from the GIHP
(Groupe d’Inte´reˆt en He´mostase Pe´riope´ratoire) [29].
Measured
concentration Recommendations
<30 ng/mL Operate
30–200 ng/mL (i) Wait up to 12 h and obtain new dosage
or (if time is not compatible with
emergency)
(ii) Operate, if abnormal bleeding:
antagonise the anticoagulant effect
200–400 ng/mL (i) Wait up to 12 h and obtain new dosage
or (if time is not compatible with
emergency)
(ii) Maximise delay surgery
(iii) Discuss hemodialysis, especially if
CrcL <50mL/min (with dabigatran only)
(iv) Operate, if abnormal bleeding:
antagonise
>400 ng/mL Overdose major haemorrhagic risk
Discuss haemodialysis before surgery (with
dabigatran only)
As thrombin time (TT) is too sensitive to dabigatran
[74], it is advisable to use a calibrated diluted thrombin
time (dTT) with dabigatran standards to estimate dabigatran
plasma concentration [74]. Therefore, Hemoclot thrombin
inhibitor (HTI) is a rapid, linear, standardized, and calibrated
assay which determines precisely plasma concentrations of
dabigatran [74].
Chromogenic anti-Xa assays are recommended to accu-
rately estimate rivaroxaban and apixaban plasma concentra-
tions higher than 30 ng/mL [75, 76].
3.4. Dealing with a Missed Dose. To minimize the risk of
bleeding, keep in mind that patients on DE for NVAF
or on rivaroxaban for NVAF and VTE prevention should
never take a double dose at the same time. If the missed
dose is within 6 hours for dabigatran and within 12 hours
for rivaroxaban, patients should take the forgotten capsule
immediately. Otherwise, if the time is exceeded, they should
just go on with the treatment without taking any capsule.
Theonly exception concernsVTE treatmentwith rivarox-
aban, where patients may take simultaneously 2 tablets of
15mg to ensure a total daily dose of 30mg.
For apixaban, there is no time schedule. Patients should
just take the forgotten capsule immediately and go on with
the treatment [26].
3.5. Adherence to Switching Procedures. To avoid hypercoag-
ulability during a switching procedure, it is important to con-
sider NOAC’s pharmacokinetics and patient comorbidities.
When VKAs are switched to NOACs, VKAs should be
discontinued and NOACs should be started as soon as the
INR is lower than 2 [77].
Inversely, if DE is switched to VKAs, physicians need to
consider the renal function before starting VKAs. Creatinine
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clearance (CrCl) influences the delay of VKA’s introduction,
which in this case, precedes dabigatran arrest (from 3 days to
1 day, if CrCl is over 50mL/min, between 30 and 50mL/min
or between 15 and 30mL/min, resp.). NOACs interfere with
an elevated INR, so that a better reflect of VKA on the INR
will appear only after 2 days of NOAC’s arrest [77].
To switch from NOACs to parenteral anticoagulants,
these last ones should be started when the next dose of
NOACs is due [77]. Inversely, NOACs should be started at
the same time or up to 2 hours before the next parenteral
anticoagulant dose. For intravenous unfractionated heparin,
NOACs should be started at the time of discontinuation of
the infusion.
3.6. Adherence to Bridging Procedures. The aim of bridging
procedures is to avoid thromboembolic events in patients at
high risk during the perioperative period.
Unfortunately, there is a lack of consensus regarding
the different bridging procedures. These differences between
national recommendations make safety studies difficult [78–
82].
Only one prospective study has recently evaluated
the peri-interventional NOAC management in unselected
patients from daily care [83]. Outcomes and bleeding risks
were compared for different types of procedure (minimal,
minor, or major) in patients under NOACs. In 22% of the
patients, NOACs were not interrupted, and in 30%, the gap
in NOAC’s intake was bridged with heparin. The rest of the
patients underwent an interruption of NOACs of maximal
3 perioperative days. Major procedures had the highest car-
diovascular and major bleeding complications. Interestingly,
the bridging therapy did not reduce cardiovascular events
but led to higher rates of major bleeding complications
compared with no bridging. But these bleedings were similar
to VKA patients who had bridging therapy before invasive
procedures.
However, a selection bias resulted from a more fre-
quent use of bridging therapy in severe procedure (most
physicians anticipated the increased cardiovascular risk in
patients undergoing major procedure). This can explain why
cardiovascular and bleeding events were more frequent in
major procedures [83].
They concluded that a continuation or short interrup-
tion of NOACs is safe for most invasive procedures and
that patients with cardiovascular risks undergoing major
procedure may benefit from bridging therapy, with as a
consequence a higher bleeding risk. As the bridging therapy
with heparin does not reduce the risk of cardiovascular
events, a benefit-risk evaluation is needed to target the
appropriate candidates who could benefit from it.
NOACs are sometimes interrupted perioperatively with-
out bridging procedure. In this case, a postoperative resump-
tion balanced between bleeding and thromboembolic risk
needs to be defined. Spyropoulos and Douketis proposed
a management based on studies assessing DE as thrombo-
prophylaxis after orthopedic surgery and on the RELY trial.
These authors suggest that NOACs should be resumed 24
hours after low bleeding risk surgery and 48–72 hours after
high bleeding risk surgery. In patients with high thrombotic
risk, consider a reduced dose of NOACs on the evening
after surgery (DE) and on the first postoperative day (DE,
rivaroxaban, and apixaban). Further studies are necessary to
validate the safety of this approach [82].
3.7. Adherence to Anesthetic Recommendations. Anesthesia
recommendations are available to decrease bleeding risks
during perioperative procedures (e.g., regional anesthesia),
especially in neuraxial anesthesia, which has potential risk of
spinal hematoma [71, 84, 85].
Extreme caution is recommended with neuraxial block-
ade for rivaroxaban and apixaban. For DE, the manufacturer
advise against its use [84].
For regional nerve blockade, ultrasound is a valuable
tool to optimize catheter placement and decrease accidental
vascular puncture [86].
Postprocedure anticoagulation (e.g., after removing
indwelling catheter) should be restarted after 8 hours minus
the time to reach maximum activity (𝑇max) (8 hours equal to
the time to establish a stable clot) [87].
4. Absence of Antidote
The absence of antidote for NOACs emphasizes the impor-
tance of implementing strategies to preventmassive bleeding.
NOACs have a relatively short half-life, so that stopping
the drug in patients without altered renal or liver function
could be already valuable to eliminate it.
In large randomized controlled trial (RCT), the num-
ber of fatal bleedings was similar between NOACs and
warfarin groups, despite absence of antidote for NOACs
[12–14]. Strategies against life-threatening bleedings under
NOACs are needed in any cases. Currently, there is no
high-quality evidence in the clinical management of severe
bleedings under NOACs but rather experience-related man-
agement. Animals and in vitro studies are guiding treatment
approaches. The discussed effectiveness of nonspecific rever-
sal therapies must be counterbalanced with their increased
thrombotic risk [88–90].
A recent paper has presented the management and
outcome of major bleeding during treatment with DE or
warfarin [91].
Dickneite and Hoffman [92] reviewed the currently
available data of PCC’s use in reversingNOAC’s anticoagulant
effects. Because of different study models, the results are
not entirely consistent. Some studies used 3F-PCCs, which
contain high concentrations of coagulation factors II, IX and
X and low and/or variable amounts of FVII. Other studies
used 4F-PCCs, which additionally contain high levels of
FVII. Due to their ability to raise the levels of these factors
and consequently enhance thrombin generation in in vitro
models, their utility to overcome the anticoagulant effects
of FIIa and FXa inhibitors is plausible. But using PCCs
to attempt to overcome the effect of an inhibitor is more
complicated than simply replacing factors that are deficient.
For example, the still present dabigatran will continue to
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inhibit thrombin activity, even if PCCs are supplied and lead
to thrombin formation.
Effectiveness and appropriate doses of PCCs still need
to be established, especially when there appear variations in
the ability of different PCCs to reverse NOAC’s anticoagulant
effects [92].
Only one of the available 4F-PCCs is able to reverse
anticoagulation due to dabigatran and rivaroxaban. The
others aremore selective for dabigatran or rivaroxaban.These
differences can be due to the wide variation in the amount of
factors II, VII, IX and X, of antithrombotic proteins (proteins
C and S) and also of anticoagulants, such as heparin and
antithrombin, among the different PCCs. For the 3F-PCCs,
two of them were able to normalize increased bleeding time
following dabigatran administration, but the effect was short-
lasting in comparison with 4F-PCC. This can be explained
by the smaller amount of FVII in 3F-PCCs and its short
half-life compared with the other factors. Activated PCCs
seem to enhancemore the parameters of thrombin generation
to supratherapeutic levels than nonactivated PCCs, but it
may be consequently at greater risk of thrombosis.Thrombin
generation appears to have the best predictive value in the
reversal of NOAC’s anticoagulant effect.
Anyway, even if some PCCs seem promising in reversing
anticoagulation due to NOACs, their effectiveness needs still
to be studied in bleeding human patients [92].
Piccini et al. analyzed the management and outcomes of
major bleeding events in patients treated with rivaroxaban
versus warfarin, using data from the ROCKET AF trial [93].
Among high-risk patients with AF who experienced major
bleeding, there was a reduction in fresh frozen plasma and
PCC’s use in the rivaroxaban group compared with the
warfarin group [93].
Other alternatives exist to treat major bleedings in
patients who do not respond to supportive measures. For
dabigatran, due to its important renal excretion, hemodialysis
can be proposed but with limited clinical experience [94–
96]. Hemodialysis can also be discussed if a patient has renal
insufficiency and needs an emergent surgery that cannot be
delayed [29].
If NOAC’s intake is recent, oral activated charcoal may
also be effective [94].
Different specific antidotes are currently under evalu-
ation. For DE, the antidote is a humanized selective and
specific monoclonal antibody fragment (aDabi-Fab), which
has no effect on other molecules. A recent study compared
its ex vivo reversal effect with PCC, aPCC, and rFVIIa
in a dabigatran anticoagulated liver trauma experimental
model. Coagulation was assessed by thromboelastometry
(TEM), global coagulation assays and diluted thrombin time.
Interestingly, rFVIIa (90 and 180 microgrammes/kg) had no
significant effect on coagulation parameters, but aDabi-Fab
(60 and 120mg/kg), PCC and aPCC (30 and 60 IU/kg) were
effective in reducing the anticoagulation effects of dabigatran
(TEM parameters and PT). In contrast, aDabi-Fab was the
only reversal agent that normalized aPTT [97].
Andexanet alpha (PRT064445), a truncated form of
enzymatically inactive factor Xa, is a universal reversal agent
for all anti-Xa inhibitors. It reverses the inhibition of factor Xa
dose-dependently, correcting the prolonged ex vivo clotting
times due to anti-Xa inhibitors [98, 99].
Another antidote currently under research is aripazine
(PER977), a small synthetic molecule that bounds several
NOACs in animal studies, without significant adverse events.
It reverses the anticoagulant activity of all clinically used
NOACs in the rat-tail injury model and also in a human ex
vivo model, using aPTT and anti-Xa analysis to measure its
reversal effect [98, 99].
In the absence of specific antidotes, it is important to
assess the degree of emergency and the patient character-
istics (which type of NOAC, timing of the last dose, drugs
interactions, comorbidities, site of bleeding, etc.) [100]. If
possible, delay the surgery until the NOAC reaches trough
concentration.
A hospital-wide policy for the management of NOAC’s
related bleedings should be easily accessible for every health
worker involved in the patient’s care.
5. Conclusions
NOACs are indisputably an important step forward in the
field of anticoagulation. However, an inappropriate use can
possibly lead to a higher risk of bleeding. This highlights the
importance of strengthening education of health care profes-
sionals and patients, that is, with regard to dose adjustment,
modalities of administration, choice of anticoagulant, and
compliance guidance.Modifiable bleeding risk factors should
also be screened and reviewed before initiation of NOACs.
Individual benefit-risk might be improved in some clinical
settings or patient subpopulations (patients at risk of supra-
or infratherapeutic plasma level) by tailoring a dose following
coagulation monitoring. Adherence to switching, bridging,
resuming, and anesthetic recommendations is crucial to
allow an optimal management of patient.
Anticoagulation with NOACs has still risks and requires
strong adherence from the patient’s side and careful supervi-
sion from the physician’s side. Furthermore, since February
2012, the EMA has imposed the development of an education
pack for patients and prescribers with regard to the safety and
effectiveness of NOACs.
A well-structured organization will help to improve the
control on side effects, tolerance, and adherence.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
Lessire Sarah, DincqAnne-Sophie, GourdinMaximilien, and
Mullier Franc¸ois contributed equally.
References
[1] S. Husted, R. De Caterina, F. Andreotti et al., “Non-vitamin
K antagonist oral anticoagulants (NOACs): no longer new or
BioMed Research International 11
novel,” Journal of Thrombosis and Haemostasis, vol. 111, no. 5,
2014.
[2] M. R. Lassen, A. Gallus, G. E. Raskob, G. Pineo, D. Chen, and
L. M. Ramirez, “Apixaban versus enoxaparin for thrombopro-
phylaxis after hip replacement,” The New England Journal of
Medicine, vol. 363, no. 26, pp. 2487–2498, 2010.
[3] M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and P.
Hornick, “Apixaban versus enoxaparin for thromboprophylaxis
after knee replacement (ADVANCE-2): a randomised double-
blind trial,”The Lancet, vol. 375, no. 9717, pp. 807–815, 2010.
[4] M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and
R. J. Portman, “Apixaban or enoxaparin for thromboprophylaxis
after knee replacement,” The New England Journal of Medicine,
vol. 361, no. 6, pp. 594–604, 2009.
[5] B. I. Eriksson, O. E. Dahl, M. H. Huo et al., “Oral dabigatran
versus enoxaparin for thromboprophylaxis after primary total
hip arthroplasty (RE-NOVATE II): a randomised, double-blind,
non-inferiority trial,”Thrombosis and Haemostasis, vol. 105, no.
4, pp. 721–729, 2011.
[6] B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Oral dabigatran
etexilate vs. subcutaneous enoxaparin for the prevention of
venous thromboembolism after total knee replacement: the
RE-MODEL randomized trial,” Journal of Thrombosis and
Haemostasis, vol. 5, no. 11, pp. 2178–2185, 2007.
[7] B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Dabigatran
etexilate versus enoxaparin for prevention of venous throm-
boembolism after total hip replacement: a randomised, double-
blind, non-inferiority trial,” The Lancet, vol. 370, no. 9591, pp.
949–956, 2007.
[8] B. I. Eriksson, L. C. Borris, R. J. Friedman et al., “Rivaroxaban
versus enoxaparin for thromboprophylaxis after hip arthro-
plasty,” The New England Journal of Medicine, vol. 358, no. 26,
pp. 2765–2775, 2008.
[9] A. K. Kakkar, B. Brenner, O. E. Dahl et al., “Extended duration
rivaroxaban versus short-term enoxaparin for the prevention of
venous thromboembolism after total hip arthroplasty: a double-
blind, randomised controlled trial,” The Lancet, vol. 372, no.
9632, pp. 31–39, 2008.
[10] M. R. Lassen, W. Ageno, L. C. Borris et al., “Rivaroxaban
versus enoxaparin for thromboprophylaxis after total knee
arthroplasty,”TheNew England Journal ofMedicine, vol. 358, no.
26, pp. 2776–2786, 2008.
[11] A. G. Turpie, M. R. Lassen, B. L. Davidson et al., “Rivaroxaban
versus enoxaparin for thromboprophylaxis after total knee
arthroplasty (RECORD4): a randomised trial,”The Lancet, vol.
373, no. 9676, pp. 1673–1680, 2009.
[12] C. B. Granger, J. H. Alexander, J. J. McMurray et al., “Apixaban
versus warfarin in patients with atrial fibrillation,” The New
England Journal of Medicine, vol. 365, pp. 981–992, 2011.
[13] M. Barry, “Dabigatran versus warfarin in patients with atrial
fibrillation,” The New England Journal of Medicine, vol. 361, no.
27, p. 2674, 2009.
[14] M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus
warfarin in nonvalvular atrial fibrillation,” The New England
Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011.
[15] E. Investigators, R. Bauersachs, S. D. Berkowitz et al., “Oral
rivaroxaban for symptomatic venous thromboembolism,” The
New England Journal of Medicine, vol. 363, pp. 2499–2510, 2010.
[16] H. R. Bu¨ller, M. H. Prins, A. W. A. Lensing et al., “Oral rivarox-
aban for the treatment of symptomatic pulmonary embolism,”
TheNew England Journal of Medicine, vol. 366, no. 14, pp. 1287–
1297, 2012.
[17] J. Mega, E. Braunwald, S. Mohanavelu et al., “Rivaroxaban
versus placebo in patients with acute coronary syndromes
(ATLAS ACS-TIMI 46): a randomised, double-blind, phase II
trial,”The Lancet, vol. 374, no. 9683, pp. 29–38, 2009.
[18] J. L. Mega, E. Braunwald, S. D. Wiviott et al., “Rivaroxaban
in patients with a recent acute coronary syndrome,” The New
England Journal of Medicine, vol. 366, pp. 9–19, 2012.
[19] E. M. Hylek, C. Held, J. H. Alexander et al., “Major bleeding in
patients with atrial fibrillation receiving apixaban or warfarin
in the ARISTOTLE trial: predictors, characteristics, and clinical
outcomes,” Journal of the American College of Cardiology, 2014.
[20] J. Harenberg, S. Marx, O. E. Dahl et al., “Interpretation of
endpoints in a network meta-analysis of new oral anticoag-
ulants following total hip or total knee replacement surgery,”
Thrombosis and Haemostasis, vol. 108, pp. 903–912, 2012.
[21] M. R. Southworth, M. E. Reichman, and E. F. Unger, “Dabiga-
tran and postmarketing reports of bleeding,”The New England
Journal of Medicine, vol. 368, pp. 1272–1274, 2013.
[22] C. Frost, S. Nepal, J. Wang et al., “Safety, pharmacokinetics and
pharmacodynamics of multiple oral doses of apixaban, a factor
Xa inhibitor, in healthy subjects,” British Journal of Clinical
Pharmacology, vol. 76, pp. 776–786, 2013.
[23] W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, “Clinical
pharmacokinetic and pharmacodynamic profile of rivaroxa-
ban,” Clinical Pharmacokinetics, vol. 53, pp. 1–16, 2014.
[24] J. Stangier and A. Clemens, “Pharmacology, pharmacokinet-
ics, and pharmacodynamics of dabigatran etexilate, an oral
direct thrombin inhibitor,” Clinical and Applied Thrombo-
sis/Hemostasis, vol. 15, supplement 1, pp. 9S–16S, 2009.
[25] A. Tamigniau, J. Douxfils, J. B. Nicolas et al., “Why, when
and how to monitor new oral anticoagulants,” Revue Me´dicale
Suisse, vol. 10, pp. 326–333, 2014.
[26] H. Heidbuchel, P. Verhamme, M. Alings et al., “European Heart
Rhythm Association Practical Guide on the use of new oral
anticoagulants in patients with non-valvular atrial fibrillation,”
Europace, vol. 15, pp. 625–651, 2013.
[27] E. Nutescu, I. Chuatrisorn, and E. Hellenbart, “Drug and
dietary interactions of warfarin and novel oral anticoagulants:
an update,” Journal of Thrombosis and Thrombolysis, vol. 31, no.
3, pp. 326–343, 2011.
[28] J. M. Walenga and C. Adiguzel, “Drug and dietary interactions
of the new and emerging oral anticoagulants,” International
Journal of Clinical Practice, vol. 64, no. 7, pp. 956–967, 2010.
[29] G. Pernod, P. Albaladejo, A. Godier et al., “Management
of major bleeding complications and emergency surgery in
patients on long-term treatment with direct oral anticoagulants,
thrombin or factor-Xa inhibitors: proposals of the working
group on perioperative haemostasis (GIHP)—March 2013,”
Archives of Cardiovascular Diseases, vol. 106, pp. 382–393, 2013.
[30] R. De Caterina, S. Husted, L. Wallentin et al., “Vitamin K
antagonists in heart disease: current status and perspectives
(Section III). Position paper of the ESC Working Group on
Thrombosis—task Force on Anticoagulants in Heart Disease,”
Thrombosis and Haemostasis, vol. 110, pp. 1087–1107, 2013.
[31] L. Poller, J. Jespersen, S. Ibrahim, and A. Pattison, “European
Action on A. Phase III studies on novel oral anticoagulants
for stroke prevention in atrial fibrillation: a look beyond
the excellent results: a rebuttal,” Journal of Thrombosis and
Haemostasis, vol. 11, pp. 1203–1205, 2013.
[32] J. Desai, J. M. Kolb, J. I. Weitz, and J. Aisenberg, “Gastroin-
testinal bleeding with the new oral anticoagulants—defining
12 BioMed Research International
the issues and the management strategies,” Thrombosis and
Haemostasis, vol. 110, pp. 205–212, 2013.
[33] “Pradaxa-H-C-829-X-13: ePAR—assessment Report—exten-
sion,” 2011, http://www.ema.europa.eu/docs/document library/
EPAR - Assessment Report - Variation/en GB/human/000829/
WC500110875.pdf.
[34] K. W. McConeghy, A. Bress, D. M. Qato, C. Wing, and E. A.
Nutescu, “Evaluation of dabigatran bleeding adverse reaction
reports in the FDA adverse event reporting system during the
first year of approval,” Pharmacotherapy, 2014.
[35] J. W. Eikelboom, L. Wallentin, S. J. Connolly et al., “Risk of
bleeding with 2 doses of dabigatran compared with warfarin in
older and younger patients with atrial fibrillation: an analysis of
the randomized evaluation of long-term anticoagulant therapy
(RE-LY) Trial,” Circulation, vol. 123, no. 21, pp. 2363–2372, 2011.
[36] K. Kirley, D. M. Qato, R. Kornfield, R. S. Stafford, and G. C.
Alexander, “National trends in oral anticoagulant use in the
United States, 2007 to 2011,” Circulation Cardiovascular Quality
and Outcomes, vol. 5, pp. 615–621, 2012.
[37] S. L. Lim and E. Maxwell, “An audit of dabigatran etexilate
prescribing in Victoria,” Medical Journal of Australia, vol. 198,
pp. 314–315, 2013.
[38] R. Sorensen, G. Gislason, C. Torp-Pedersen et al., “Dabigatran
use in Danish atrial fibrillation patients in 2011: a Nationwide
Study,” BMJ Open, vol. 3, article e002758, 2013.
[39] B. Carley, S. Griesbach, T. Larson, and K. Krueger, “Assessment
of dabigatran utilization and prescribing patterns for atrial
fibrillation in a physician group practice setting,”The American
Journal of Cardiology, vol. 113, pp. 650–654, 2014.
[40] C. Escobar and V. Barrios, “Dabigatran and bleeding risk: the
importance of a correct prescription,”The Journal of Emergency
Medicine, 2013.
[41] A. Troncoso and E. Diogene, “Dabigatran and rivaroxaban
prescription for atrial fibrillation in Catalonia, Spain: the need
to manage the introduction of new drugs,” European Journal of
Clinical Pharmacology, vol. 70, pp. 249–250, 2014.
[42] “European Medicine Agency—xarelto: summary of Product
Characteristics,” 2013, http://www.ema.europa.eu/docs/en GB/
document library/EPAR - Product Information/human/000944/
WC500057108.pdf.
[43] “European Medicine Agency—pradaxa: summary of Product
Characteristics,” 2013, http://www.ema.europa.eu/docs/en
GB/document library/EPAR - Product Information/human/
000829/WC500041059.pdf.
[44] “European Medicine Agency—eliquis: summary of Product
Characteristics,” 2014, http://www.ema.europa.eu/docs/en
GB/document library/EPAR - Product Information/human/
002148/WC500107728.pdf.
[45] W. Pfeilschifter, S. Luger, R. Brunkhorst, E. Lindhoff-Last,
and C. Foerch, “The gap between trial data and clinical
practice—an analysis of case reports on bleeding complications
occurring under dabigatran and rivaroxaban anticoagulation,”
Cerebrovascular Disease, vol. 36, pp. 115–119, 2013.
[46] A. Hellden, I. Odar-Cederlof, G. Nilsson et al., “Renal func-
tion estimations and dose recommendations for dabigatran,
gabapentin and valaciclovir: a data simulation study focused on
the elderly,” BMJ Open, vol. 3, article e002686, 2013.
[47] P. K. Maccallum, R. Mathur, S. A. Hull et al., “Patient safety
and estimation of renal function in patients prescribed new
oral anticoagulants for stroke prevention in atrial fibrillation: a
Cross-Sectional Study,” BMJ Open, vol. 3, article e003343, 2013.
[48] K. Moore, S. Vaidyanathan, C. Damaraju, and L. Fields, “The
relative bioavailability of single-dose rivaroxaban, a novel oral
anticoagulant and a selective direct factor Xa inhibitor, admin-
istered orally (as a whole or crushed tablet) and via nasogastric
tube (as a crushed tablet suspension),”Pharmacotherapy, vol. 32,
article 2, 2012.
[49] J. P. Patel, L. N. Roberts, and R. Arya, “Anticoagulating obese
patients in the modern era,” British Journal of Haematology, vol.
155, no. 2, pp. 137–149, 2011.
[50] “Pradaxa: full Prescribing Information,” 2013, http://www.
accessdata.fda.gov/drugsatfda docs/label/2013/022512s017lbl.
pdf.
[51] D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck, “Body
weight has limited influence on the safety, tolerability, phar-
macokinetics, or pharmacodynamics of rivaroxaban (BAY 59-
7939) in healthy subjects,” Journal of Clinical Pharmacology, vol.
47, no. 2, pp. 218–226, 2007.
[52] W. Mueck, B. I. Eriksson, K. A. Bauer et al., “Population
pharmacokinetics and pharmacodynamics of rivaroxaban—an
oral, direct factor Xa inhibitor—in patients undergoing major
orthopaedic surgery,” Clinical Pharmacokinetics, vol. 47, no. 3,
pp. 203–216, 2008.
[53] V. V. Upreti, J. Wang, Y. C. Barrett et al., “Effect of extremes
of body weight on the pharmacokinetics, pharmacodynamics,
safety and tolerability of apixaban in healthy subjects,” British
Journal of Clinical Pharmacology, vol. 76, pp. 908–916, 2013.
[54] “Food and Drug Administration—eliquis: full Prescribing
Information,” 2014, http://www.accessdata.fda/drugsatfda
docs/label/2012/202155s000lbl.pdf.
[55] “Food and drug Administration—eliquis: clinical Pharma-
cology & Biopharmaceutical Review(s),” 2014, http://www.
accessdata.fda.gov/drugsatfda docs/nda/2012/202155Orig1s000
ClinPharmR.pdf.
[56] J. Stangier, H. Sta¨hle, K. Rathgen, W. Roth, and K. Shakeri-
Nejad, “Pharmacokinetics and pharmacodynamics of dabi-
gatran etexilate, an oral direct thrombin inhibitor, are not
affected by moderate hepatic impairment,” Journal of Clinical
Pharmacology, vol. 48, no. 12, pp. 1411–1419, 2008.
[57] J. Graff and S. Harder, “Anticoagulant therapy with the oral
direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban
and the thrombin inhibitor dabigatran etexilate in patients
with hepatic impairment,”Clinical Pharmacokinetics, vol. 52, pp.
243–254, 2013.
[58] D. Kubitza, A. Roth, M. Becka et al., “Effect of hepatic impair-
ment on the pharmacokinetics and pharmacodynamics of a
single dose of rivaroxaban, an oral, direct Factor Xa inhibitor,”
British Journal of Clinical Pharmacology, vol. 76, pp. 89–98, 2013.
[59] C. E. Frost, Z. Yu, J. Wang et al., “Single-dose safety and phar-
macokinetics of apixaban in subjects with mild or moderate
hepatic impairment,” Clinical Pharmacology & Therapeutics,
vol. 85, supplement 1, article PI-84, p. S34, 2009.
[60] F. Rodeghiero, A. Tosetto, T. Abshire et al., “ISTH/SSC bleeding
assessment tool: a standardized questionnaire and a proposal
for a new bleeding score for inherited bleeding disorders,”
Journal of Thrombosis and Haemostasis, vol. 8, no. 9, pp. 2063–
2065, 2010.
[61] S. Apostolakis, D.A. Lane,H. Buller, andG.Y. Lip, “Comparison
of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for
the prediction of clinically relevant bleeding in anticoagulated
patients with atrial fibrillation: the AMADEUS trial,”Thrombo-
sis and Haemostasis, vol. 110, pp. 1074–1079, 2013.
BioMed Research International 13
[62] S. Burgess, N. Crown,M. L. Louzada, G. Dresser, R. B. Kim, and
A. Lazo-Langner, “Clinical performance of bleeding risk scores
for predicting major and clinically relevant non-major bleeding
events in patients receiving warfarin,” Journal ofThrombosis and
Haemostasis, vol. 11, pp. 1647–1654, 2013.
[63] P. A. Reilly, T. Lehr, S. Haertter et al., “The effect of dabi-
gatran plasma concentrations and patient characteristics on
the frequency of ischemic stroke and major bleeding in atrial
fibrillation patients: theRE-LYTrial (RandomizedEvaluation of
Long-Term AnticoagulationTherapy),” Journal of the American
College of Cardiology, vol. 63, pp. 321–328, 2014.
[64] H. Ten Cate, “Monitoring new oral anticoagulants, managing
thrombosis, or both?”Thrombosis and Haemostasis, vol. 107, no.
5, pp. 803–805, 2012.
[65] K.-H. Liesenfeld, T. Lehr, C. Dansirikul et al., “Population phar-
macokinetic analysis of the oral thrombin inhibitor dabigatran
etexilate in patientswith non-valvular atrial fibrillation from the
RE-LY trial,” Journal of Thrombosis and Haemostasis, vol. 9, no.
11, pp. 2168–2175, 2011.
[66] G. Freyburger, G. MacOuillard, S. Labrouche, and F. Sztark,
“Coagulation parameters in patients receiving dabigatran etex-
ilate or rivaroxaban: two observational studies in patients
undergoing total hip or total knee replacement,” Thrombosis
Research, vol. 127, no. 5, pp. 457–465, 2011.
[67] H. Mani and E. Lindhoff-Last, “Main considerable factors for
correct laboratory test interpretation under DOA treatment,”
Thrombosis Journal, vol. 11, article 22, 2013.
[68] M.M. Samama, “Coagulation Assays in Patients with NewOral
Anticoagulants (NOACs): why? When?” Drug Development
Research, vol. 74, article 7, 2013.
[69] H. Ten Cate, “New oral anticoagulants: discussion on monitor-
ing and adherence should start now!,” Thrombosis Journal, vol.
11, article 8, 2013.
[70] T. Baglin, D. Keeling, and S. Kitchen, “Effects on routine
coagulation screens and assessment of anticoagulant intensity
in patients taking oral dabigatran or rivaroxaban: guidance
from the British Committee for Standards in Haematology,”
British Journal of Haematology, vol. 159, pp. 427–429, 2012.
[71] A. G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas,
“Management consensus guidance for the use of rivaroxaban—
an oral, direct factor Xa inhibitor,”Thrombosis andHaemostasis,
vol. 108, pp. 876–886, 2012.
[72] T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W.
Ageno, “Measuring Oral Direct Inhibitors (ODIs) of thrombin
and factor Xa: a recommendation from the Subcommittee on
Control ofAnticoagulation of the Scientific and Standardisation
Committee of the International Society on Thrombosis and
Haemostasis,” Journal of Thrombosis and Haemostasis, 2013.
[73] Y. C. Barrett, J. Wang, Y. Song et al., “A randomised assessment
of the pharmacokinetic, pharmacodynamic and safety inter-
action between apixaban and enoxaparin in healthy subjects,”
Thrombosis and Haemostasis, vol. 107, no. 5, pp. 916–924, 2012.
[74] J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and
J.-M. Dogne´, “Impact of dabigatran on a large panel of routine
or specific coagulation assays: laboratory recommendations for
monitoring of dabigatran etexilate,”Thrombosis and Haemosta-
sis, vol. 107, no. 5, pp. 985–997, 2012.
[75] J. Douxfils, C. Chatelain, B. Chatelain, J.-M. Dogne´, and F.
Mullier, “Impact of apixaban on routine and specific coag-
ulation assays: a practical laboratory guide,” Thrombosis and
Haemostasis, vol. 110, pp. 283–294, 2013.
[76] J. Douxfils, A. Tamigniau, B. Chatelain et al., “Comparison of
calibrated chromogenic anti-Xa assay and PT tests with LC-
MS/MS for the therapeutic monitoring of patients treated with
rivaroxaban,”Thrombosis andHaemostasis, vol. 110, pp. 723–731,
2013.
[77] M. V. Huisman, G. Y. H. Lip, H.-C. Diener, M. Brueckmann,
J. Van Ryn, and A. Clemens, “Dabigatran etexilate for stroke
prevention in patients with atrial fibrillation: resolving uncer-
tainties in routine practice,” Thrombosis and Haemostasis, vol.
107, no. 5, pp. 838–847, 2012.
[78] T. H. Baron, P. S. Kamath, and R. D. McBane, “Management
of antithrombotic therapy in patients undergoing invasive
procedures,”TheNew England Journal of Medicine, vol. 368, pp.
2113–2124, 2013.
[79] S. A. Kozek-Langenecker, “Perioperative management issues of
direct oral anticoagulants,” Seminars in Hematology, 2014.
[80] A. Liew and J. Douketis, “Perioperativemanagement of patients
who are receiving a novel oral anticoagulant,” Internal and
Emergency Medicine, vol. 8, pp. 477–484, 2013.
[81] P. Sie´, C. M. Samama, A. Godier et al., “Surgery and invasive
procedures in patients on long-term treatment with direct oral
anticoagulants: thrombin or factor-Xa inhibitors. Recommen-
dations of the Working Group on perioperative haemostasis
and the French Study Group on thrombosis and haemostasis,”
Archives of CardiovascularDiseases, vol. 104, no. 12, pp. 669–676,
2011.
[82] A. C. Spyropoulos and J. D. Douketis, “How I treat anticoag-
ulated patients undergoing an elective procedure or surgery,”
Blood, vol. 120, pp. 2954–2962, 2012.
[83] J. Beyer-Westendorf, V. Gelbricht, K. Forster et al., “Peri-
interventionalmanagement of novel oral anticoagulants in daily
care: results from the prospective Dresden NOAC registry,”
European Heart Journal, 2014.
[84] W. Gogarten, E. Vandermeulen, H. Van Aken, S. Kozek, J. V.
Llau, and C.M. Samama, “Regional anaesthesia and antithrom-
botic agents: recommendations of the European Society of
Anaesthesiology,” European Journal of Anaesthesiology, vol. 27,
no. 12, pp. 999–1015, 2010.
[85] J. H. Levy, D. Faraoni, J. L. Spring, J. D. Douketis, and
C. M. Samama, “Managing new oral anticoagulants in the
perioperative and intensive care unit setting,” Anesthesiology,
vol. 118, pp. 1466–1474, 2013.
[86] J. V. Llau and R. Ferrandis, “New anticoagulants and regional
anesthesia,” Current Opinion in Anaesthesiology, vol. 22, no. 5,
pp. 661–666, 2009.
[87] N. Rosencher, M.-P. Bonnet, and D. I. Sessler, “Selected new
antithrombotic agents and neuraxial anaesthesia for major
orthopaedic surgery: management strategies,” Anaesthesia, vol.
62, no. 11, pp. 1154–1160, 2007.
[88] S. Kaatz and M. Crowther, “Reversal of target-specific oral
anticoagulants,” Journal ofThrombosis andThrombolysis, vol. 36,
pp. 195–202, 2013.
[89] S. Kaatz, P. A. Kouides, D. A. Garcia et al., “Guidance on the
emergent reversal of oral thrombin and factor Xa inhibitors,”
American Journal of Hematology, vol. 87, no. 1, pp. S141–S145,
2012.
[90] D. M. Siegal, D. A. Garcia, and M. A. Crowther, “How I treat
target-specific oral anticoagulant-associated bleeding,” Blood,
vol. 123, pp. 1152–1158, 2014.
[91] A.Majeed, H. G. Hwang, S. J. Connolly et al., “Management and
outcomes of major bleeding during treatment with dabigatran
or warfarin,” Circulation, vol. 128, pp. 2325–2332, 2013.
14 BioMed Research International
[92] G. Dickneite and M. Hoffman, “Reversing the new oral antico-
agulants with prothrombin complex concentrates (PCCs): what
is the evidence?”Thrombosis and Haemostasis, vol. 111, pp. 189–
198, 2014.
[93] J. P. Piccini, J. Garg, M. R. Patel et al., “Management of
major bleeding events in patients treated with rivaroxaban vs.
warfarin: results from the ROCKET AF trial,” European Heart
Journal, 2014.
[94] J. VanRyn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a
novel, reversible, oral direct thrombin inhibitor: interpretation
of coagulation assays and reversal of anticoagulant activity,”
Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010.
[95] M. R. Wanek, E. T. Horn, S. Elapavaluru, S. C. Baroody, and G.
Sokos, “Safe use of hemodialysis for dabigatran removal before
cardiac surgery,”Annals of Pharmacotherapy, vol. 46, article e21,
2012.
[96] T. E. Warkentin, P. Margetts, S. J. Connolly, A. Lamy, C.
Ricci, and J. W. Eikelboom, “Recombinant factor VIIa (rFVIIa)
and hemodialysis to manage massive dabigatran-associated
postcardiac surgery bleeding,” Blood, vol. 119, no. 9, pp. 2172–
2174, 2012.
[97] O. Grottke, J. van Ryn, H. M. Spronk, and R. Rossaint,
“Prothrombin complex concentrates and a specific antidote
to dabigatran are effective ex-vivo in reversing the effects of
dabigatran in an anticoagulation/liver trauma experimental
model,” Critical Care, vol. 18, article R27, 2014.
[98] G. Lu, F. R. DeGuzman, S. J. Hollenbach et al., “A specific
antidote for reversal of anticoagulation by direct and indirect
inhibitors of coagulation factor Xa,”NatureMedicine, vol. 19, pp.
446–451, 2013.
[99] C. Ward, G. Conner, G. Donnan, A. Gallus, and S. McRae,
“Practical management of patients on apixaban: a consensus
guide,”Thrombosis Journal, vol. 11, article 27, 2013.
[100] A.Majeed and S. Schulman, “Bleeding and antidotes in neworal
anticoagulants,” Best Practice & Research Clinical Haematology,
vol. 26, pp. 191–202, 2013.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
